sagopilone + placebo + prednisone

Sagopilone + placebo + prednisone is a combination regimen used in clinical trials for the treatment of advanced cancers, particularly metastatic castration-resistant prostate cancer (CRPC) and ovarian cancer. Sagopilone is a fully synthetic epothilone that acts as a microtubule-stabilizing agent, disrupting cell division and inducing apoptosis in tumor cells. Prednisone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties commonly used to manage symptoms and side effects in cancer therapy. The "placebo" component refers to an inert substance administered as part of randomized controlled trial designs to assess the efficacy or safety of adjunctive therapies (e.g., acetyl-L-carnitine for neuropathy prevention). This combination has been studied primarily for its antitumor activity and safety profile; peripheral neuropathy is noted as the most clinically relevant toxicity associated with sagopilone[2][5][6].